Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 9/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10084840 | 0.87 | IMPDH2 (0.50) | IMPDH2SLC6A4XDHMAOA | |
| SCHEMBL15298774 | 0.86 | IMPDH2 (0.62) | IMPDH2MAOAL3MBTL1LMNAHTT | |
| SCHEMBL7273946 | 0.81 | IMPDH2 (0.59) | IMPDH2SLC6A4XDHL3MBTL1 | |
| SCHEMBL2417482 | 0.81 | IMPDH2 (0.59) | IMPDH2SLC6A4XDHSMN1; SMN2 | |
| SCHEMBL16455429 | 0.81 | IMPDH2 (0.59) | IMPDH2SLC6A4XDHLMNASMN1; SMN2 | |
| SCHEMBL13385265 | 0.81 | IMPDH2 (0.59) | IMPDH2SLC6A4XDH | |
| SCHEMBL22450677 | 0.81 | IMPDH2 (0.59) | IMPDH2SLC6A4XDHHTTSMN1; SMN2 | |
| SCHEMBL1777994 | 0.78 | IMPDH2 (0.56) | IMPDH2SLC6A4MAOAL3MBTL1HTT | |
| SCHEMBL16743115 | 0.78 | IMPDH2 (0.56) | IMPDH2SLC6A4XDHSMN1; SMN2 | |
| SCHEMBL9919097 | 0.78 | IMPDH2 (0.48) | IMPDH2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| EP-2616460-B1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMA CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-9090572-B2 | Substituted quinoxalines compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-28 | — | — | US | disclosed |
| US-9090572-B2 | Substituted quinoxalines compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-28 | — | — | US | disclosed |
| CN-104788359-A | Synthesis method of copper-promoted 3-cyano-substituted-indole compound | UNIV HUNAN | 2015-07-22 | — | — | CN | disclosed |
| US-9040530-B2 | 1,2,4-triazine-6-carboxamide kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2013-10-03 | — | — | US | disclosed |
| EP-0337547-B1 | Spirocyclic compounds incorporating five-membered rings with two heteroatoms | MERCK SHARP & DOHME (GB) | 1994-03-02 | — | — | EP | disclosed |
| US-4940703-A | Spirocyclic compounds incorporating five-membered rings with two heteroatoms for treating psychotic disorders, etc. | MERCK SHARP & DOHME LIMITED (GB) | 1990-07-10 | — | — | US | disclosed |
| EP-0337547-A1 | Spirocyclic compounds incorporating five-membered rings with two heteroatoms | MERCK SHARP & DOHME LTD. (GB) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | IMPDH2 3757/4885SLC6A4 115/4885XDH 80/4885 |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | IMPDH2 3520/4885SLC6A4 95/4885XDH 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.